Effect of Muvalaplin on the reduction of major adverse cardiovascular events in adults with elevated Lipoprotein(a), who have had a prior atherosclerotic cardiovascular event, or are at risk for a first atherosclerotic cardiovascular event.

Effect of Orforglipron on patients with established CVD and/or CKD.

Effect of Tirzapetide vs Retatrutide or Placebo on participants with fatty liver disease with obesity.

Effect of Zilebesiran in addition to Standard of Care in adults with uncontrolled hypertension and CVD or at risk of CVD.

Effect of Retatrutide on participants without type 2 diabetes who have obesity and OSA.

Effect of Retatrutide on participants with or without type 2 diabetes who have obesity.

Effect of Retatrutide on participants with CVD and/or CKD.

Effect of Retatrutide on participants without type 2 diabetes who have obesity and knee OA.

Effect of Tirzapetide on Adolescents with Obesity and 2 CV risk factors.

Effect of Evolocumab on CV events in patients with CV risk but no prior MI or CVA.

Effect of Tirzapetide vs Dulaglutide on CV events in patients with Type 2 Diabetes.